Use of recombinant expressed protein in prevention and / or treatment of respiratory disease

By developing the fusion protein GRFT and the recombinant expression protein GL25E, the prevention and treatment problems of respiratory diseases caused by influenza A virus and the new coronavirus co-infection have been solved, and efficient inhibition of influenza A virus and the new coronavirus has been achieved, providing a broad spectrum Preventive and therapeutic options, especially suitable for nasal administration.

WO2024239980A1PCT designated stage expired Publication Date: 2024-11-28SHANXI JINBO BIO PHARMACEUTICAL CO LTD +1

Patent Information

Application Number
PCT/CN2024/092300
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-25
Filing Date
2024-05-10
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

The prior art is difficult to effectively prevent and treat respiratory diseases caused by co-infection of influenza A virus and the new coronavirus, especially in the context of the global COVID-19 pandemic, with a lack of broad-spectrum inhibitors to co-infection potential.

Method used

A fusion protein GRFT and recombinant expression protein GL25E were developed to form polypeptides that can be directly linked or linked by flexible linkers by fusing anti-influenza virus peptides with anti-coronavirus peptides, enhance their antiviral activity and administered through nasal form. Protect prevention and treatment options.

Benefits of technology

GRFT and GL25E can effectively inhibit the proliferation of influenza A virus and the new coronavirus, provide effective prevention and treatment options for co-infection, and are particularly suitable as nasal administration drugs, with good patient compliance and safety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCTCN2024092300-FTAPPB-I100001
    Figure PCTCN2024092300-FTAPPB-I100001
  • Figure PCTCN2024092300-FTAPPB-I100002
    Figure PCTCN2024092300-FTAPPB-I100002
  • Figure PCTCN2024092300-FTAPPB-I100003
    Figure PCTCN2024092300-FTAPPB-I100003
Patent Text Reader

Abstract

A use of a recombinant expressed protein in prevention and / or treatment of a respiratory disease. Provided is a use of two recombinant expressed proteins in preparation of a drug for prevention and / or treatment of a respiratory disease. The respiratory disease is caused by influenza A virus infection or co-infection of influenza A virus and novel coronavirus. GRFT has an amino acid sequence shown in SEQ ID NO: 1, and GL25E has an amino acid sequence shown in SEQ ID NO: 2. The recombinant protein GRFT and fusion protein GL25E can effectively inhibit the influenza A virus infection, wherein GL25E is formed by coupling an EK1 polypeptide on the basis of GRFT, the recombinant protein GRFT and fusion protein GL25E have good inhibitory activity against influenza A virus, also have good inhibitory activity against the co-infection of influenza virus and novel coronavirus, and can be used in preparation of drugs for prevention and / or treatment of respiratory diseases caused by influenza virus and the co-infection of influenza virus and coronavirus.
Need to check novelty before this filing date? Find Prior Art

Description

Application of recombinant expressed proteins in preventing and / or treating respiratory diseases

[0001] This application claims the priority benefit of the Chinese invention patent application with application date of May 25, 2023, application number 202310601537.2, and invention name “Application of recombinantly expressed proteins in the prevention and / or treatment of respiratory diseases”. Technical Field

[0002] The present invention relates to the field of protein drugs, and in particular to the use of two recombinantly expressed proteins, GRFT and GL25E, in drugs for preventing and / or treating respiratory diseases. Background Art

[0003] Influenza virus is a single-stranded negative-sense RNA virus with an envelope protein, belonging to the Orthomyxoviridae family. Influenza A virus (IAV) contains eight negative-sense single-stranded viral RNA (vRNA) gene segments, including viral polymerase basic protein 1 (PB1), polymerase basic protein 2 (PB2), polymerase acidic protein (PA), nucleoprotein (NP), matrix protein (M), and nonstructural protein (NS).

[0004] Influenza viruses (IV) are divided into four subtypes: A (A), B (B), C (C), and D (D), based on the antigenicity of their viral nucleoprotein (NP) and matrix protein M1. Most influenza epidemics are caused by one or two influenza viruses, with influenza A virus (IAV) being the most common influenza virus during the flu season. Respiratory symptoms caused by influenza viruses include fever, sore throat, runny nose, dry cough, headache, sore throat, runny nose, muscle or body aches, or gastrointestinal symptoms (vomiting and diarrhea). Influenza A viruses can be divided into 18 HA (H1-H18) subtypes and 11 NA (N1-N11) subtypes based on the antigenicity and genetic characteristics of their surface antigens hemagglutinin (HA) and neuraminidase (NA). H1-H16 and N1-N9 can be arbitrarily combined to form different subtypes of influenza viruses (such as H1N1, H7N9, and H3N2). The two new subtypes, H17N10 and H18N11, are influenza A-like viruses isolated from bats.

[0005] HA is initially translated into the HA0 precursor, which undergoes proteolysis and glycosylation to form a trimer consisting of three HA1 and three HA2 subunits. The HA0 precursor cannot initiate membrane fusion and must first be cleaved by proteases into the HA1 / HA2 complex before it can fuse with the membrane. Human HA0 proteins and low-pathogenic avian influenza viruses are activated by cleavage outside the cell by trypsin-like proteases or other soluble proteases. The mature HA1 / HA2 complex consists of a membrane-proximal stalk domain containing the N-terminus and C-terminus of HA1 and the entire HA2, and a membrane-distal receptor-binding domain containing receptor-binding and residual esterase subdomains. After viral budding and HA0 cleavage, influenza virus is able to infect new host cells. To do this, the HA protein binds to a sialic acid-containing receptor, and the virion is then internalized through endocytosis (clathrin-mediated or clathrin-independent) or macropinocytosis. During endocytosis, influenza virions are sequentially exposed to lower pH in early endosomes (pH 6.0–6.5), late endosomes (pH 5.0–5.5), and lysosomes (pH 4.6–5.0). The cleaved HA1 / HA2 is trapped in a high-energy (metastable) conformation and, biotriggered by low pH, undergoes an irreversible conformational change, leading to membrane fusion. If virions are exposed to sufficiently low pH outside the host or host cell, the HA protein is prematurely activated to irreversibly refold, thereby inactivating the virion.

[0006] Influenza virus transmission among humans occurs primarily through respiratory droplets, direct contact, contact between susceptible individuals and infected individuals, or respiratory mites. Unlike human influenza viruses, avian influenza viruses are primarily transmitted through fecal-to-fecal, fecal-oral, or fecal-respiratory routes during migration of wild birds. The HAs of human influenza viruses have a high affinity for α-2,6 sialic acid receptors, while the HAs of most avian influenza viruses bind to α-2,3 sialic acid. Only α-2,6 sialic acid receptors are present in the human upper respiratory tract, while α-2,3 sialic acid receptors are located in the lower respiratory tract, in the respiratory bronchial alveoli and interstitial cell walls. In poultry, α-2,3 sialic acid receptors are primarily distributed in the intestinal epithelial cells.

[0007] Epidemics caused by influenza viruses are generally categorized as seasonal and pandemic. Seasonal influenza occurs almost annually, and according to the World Health Organization, approximately 290,000 to 650,000 people die annually worldwide from respiratory illnesses caused by influenza infection. Over the past 100 years, humanity has experienced four global influenza pandemics: the Spanish flu (H1N1) of 1918, the Asian flu (H3N2) of 1957, the H3N2 flu of 1968, and the influenza A (H1N1) of 2009. In the past 20 years, cross-species transmission of highly pathogenic H5N1 and H7N9 strains has occurred sporadically, posing a significant threat to public health. Therefore, the development of highly effective and broad-spectrum anti-influenza A drugs is necessary.

[0008] Recent studies have found that coinfection with COVID-19 and influenza can lead to exacerbated disease. Therefore, in the context of the global COVID-19 pandemic, it is necessary to develop broad-spectrum inhibitors that can simultaneously protect against influenza and COVID-19, potentially preventing and treating coinfections.

[0009] Summary of the Invention

[0010] In one aspect, the present invention provides a fusion protein comprising a first polypeptide and a second polypeptide, wherein the first polypeptide comprises the amino acid sequence shown in SEQ ID NO.1 or a variant amino acid sequence thereof having one or more amino acid mutations, and the second polypeptide comprises the amino acid sequence shown in SEQ ID NO.3 or a variant amino acid sequence thereof having one or more amino acid mutations, and the first polypeptide and the second polypeptide are directly connected or connected through a linker.

[0011] In one embodiment, the first polypeptide has anti-influenza activity. In one embodiment, the second polypeptide has anti-coronavirus activity.

[0012] In one embodiment, the first polypeptide is at the N-terminus or C-terminus of the second polypeptide.

[0013] In one embodiment, the linker is a flexible linker.

[0014] In one embodiment, the linker is (GS)n, (GGS)n, (GGGS)n, or (GGGGS)n, where n is an integer of 1-20, 2-15, 3-10, or 4-8.

[0015] In one embodiment, the linker is (GGGGS)5.

[0016] In one embodiment, the fusion protein comprises the amino acid sequence shown in SEQ ID NO.2.

[0017] In one embodiment, the mutation is a substitution, insertion, deletion and / or addition, preferably a conservative amino acid substitution.

[0018] In one aspect, the invention provides a nucleic acid encoding a fusion polypeptide as described herein.

[0019] In one aspect, the invention provides a vector comprising a nucleic acid according to the present invention,

[0020] In one embodiment, the vector comprises nucleotides encoding a purification tag, nucleotides encoding a leader and / or regulatory elements.

[0021] In one embodiment, the purification tag is selected from a His tag, a GST tag, an MBP tag, a SUMO tag or a NusA tag.

[0022] In one embodiment, the regulatory element is selected from a promoter, a terminator and / or an enhancer.

[0023] In one aspect, the invention provides a host cell comprising a nucleic acid as described herein or a vector as described herein.

[0024] In one embodiment, the host cell is a eukaryotic cell or a prokaryotic cell.

[0025] In one embodiment, the eukaryotic cell is a yeast cell, an animal cell and / or an insect cell, and / or the prokaryotic cell is an E. coli cell.

[0026] In one aspect, the present invention provides a pharmaceutical composition comprising a fusion polypeptide as described herein, a nucleic acid as described herein, a nucleic acid as described herein and / or a vector as described herein, and further comprising a pharmaceutically acceptable carrier.

[0027] In one embodiment, the composition comprises an additional anti-influenza drug and / or an anti-coronavirus drug.

[0028] In one embodiment, the anti-influenza drug is an anti-influenza A drug, for example selected from oseltamivir, arbidol, mabaloxavir, peramivir and zanamivir.

[0029] In one embodiment, the anti-coronavirus drug is selected from monolavir, namatevir, ritonavir, azithromycin, ambavirimab, romisvir, sotrovimab, imdevimab, casirivimab, tixagevimab, cilgavimab, bamlanivimab, etesevimab, amubarvimab and romlusevimab.

[0030] In one embodiment, the composition is in the form of a tablet, capsule, pellet, aerosol, pill, powder, solution, suspension, emulsion, granule, liposome, transdermal agent, or lyophilized powder.

[0031] In one aspect, the present invention provides an in vitro method for inhibiting the proliferation of influenza virus and / or coronavirus, comprising contacting a cell with a fusion protein as described herein and / or a GRFT protein comprising the amino acid sequence shown in SEQ ID NO.1; wherein the influenza virus is influenza A virus and the coronavirus is SARS-CoV-2.

[0032] In one embodiment, the influenza A virus is selected from H1N1, H3N2, H5N1 and H7N9.

[0033] In one embodiment, SARS-CoV-2 is selected from wild-type SARS-CoV-2 and mutants in which the S protein is mutated, for example, selected from D614G, Omicron BA.1, Omicron BA.2, Omicron BA.3, Omicron BA.5, Omicron BF.7, Omicron BQ.1 and Omicron XBB.

[0034] In one aspect, the present invention provides the use of the fusion protein, nucleic acid, pharmaceutical composition, and / or GRFT protein comprising the amino acid sequence shown in SEQ ID NO. 1 described herein in the preparation of a medicament for preventing and / or treating a respiratory disease, wherein the respiratory disease is caused by infection with influenza A virus and / or SARS-CoV-2, preferably caused by infection with influenza A virus or a combination of influenza A virus and SARS-CoV-2. For example, the disease is influenza or influenza combined with SARS-CoV-2.

[0035] In one embodiment, the influenza A virus is selected from H1N1, H3N2, H5N1 and H7N9; and / or the severe acute respiratory syndrome coronavirus 2 is selected from wild-type SARS-CoV-2 and a mutant strain with a mutation in the S protein, for example, selected from D614G, Omicron BA.1, Omicron BA.2, Omicron BA.3, Omicron BA.5, Omicron BF.7, Omicron BQ.1 and Omicron XBB.

[0036] In one embodiment, the drug is a drug for nasal administration.

[0037] In one embodiment, the medicament is a prophylactic medicament.

[0038] In one embodiment, the drug is administered from 3 hours before coronavirus infection to 3 hours after coronavirus infection, from 2 hours before coronavirus infection to 2 hours after coronavirus infection, from 1 hour before coronavirus infection to 1 hour after coronavirus infection, or from 0.5 hours before coronavirus infection to 0.5 hours after coronavirus infection.

[0039] In one embodiment, the medicament prevents and / or treats respiratory diseases by inhibiting the cellular endocytosis mediated by hemagglutinin, a surface protein of influenza A virus.

[0040] In one aspect, the present invention provides a method for increasing the anti-coronavirus activity of an anti-coronavirus polypeptide, increasing the anti-influenza virus activity of an anti-influenza virus, and / or adding anti-influenza virus activity while increasing the anti-coronavirus activity of an anti-coronavirus polypeptide, comprising fusing an anti-influenza virus polypeptide with an anti-coronavirus polypeptide, wherein the anti-coronavirus polypeptide comprises the amino acid sequence shown in SEQ ID NO.3 or a variant amino acid sequence thereof having one or more amino acid mutations, and the anti-influenza virus polypeptide comprises the amino acid sequence shown in SEQ ID NO.1 or a variant amino acid sequence thereof having one or more amino acid mutations, and the fusion is performed by directly connecting the anti-influenza virus polypeptide and the anti-coronavirus polypeptide or connecting them through a linker; wherein the coronavirus is SARS-CoV-2; and the influenza virus is influenza A virus.

[0041] In one embodiment, the influenza A virus is selected from H1N1, H3N2, H5N1 and H7N9.

[0042] In one embodiment, SARS-CoV-2 is selected from wild-type SARS-CoV-2 and mutants in which the S protein is mutated, for example, selected from D614G, Omicron BA.1, Omicron BA.2, Omicron BA.3, Omicron BA.5, Omicron BF.7, Omicron BQ.1 and Omicron XBB.

[0043] In one embodiment, the anti-coronavirus polypeptide is at the N-terminus or C-terminus of the anti-influenza polypeptide.

[0044] In one embodiment, the linker is a flexible linker.

[0045] In one embodiment, the linker is (GS)n, (GGS)n, (GGGS)n, or (GGGGS)n, where n is an integer of 1-20, 2-15, 3-10, or 4-8.

[0046] In one embodiment, the linker is (GGGGS)5.

[0047] In one embodiment, the fusion protein comprises the amino acid sequence shown in SEQ ID NO.2.

[0048] In one embodiment, the mutation is a substitution, insertion, deletion and / or addition, preferably a conservative amino acid substitution.

[0049] The present invention provides a medicine for preventing and / or treating respiratory diseases, which comprises GRFT and GL25E.

[0050] The respiratory disease can be caused by influenza A virus infection or by influenza A virus combined with the new coronavirus. The GRFT has the nucleotide sequence shown in SEQ ID NO.1, and the GL25E has the nucleotide sequence shown in SEQ ID NO.2.

[0051] In one embodiment, the influenza viruses include H1N1, H3N2, H5N1, and H7N9, and the novel coronavirus is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

[0052] In one embodiment, the novel coronavirus includes a wild-type coronavirus and a mutant strain with a mutation in the S protein, wherein the mutant strain with a mutation in the S protein includes one or more of D614G, Omicron BA.1, Omicron BA.2, Omicron BA.3, Omicron BA.5, Omicron BF.7, Omicron BQ.1, and Omicron XBB.

[0053] In one embodiment, the respiratory disease includes influenza or influenza combined with novel coronavirus pneumonia.

[0054] In one embodiment, the drug for preventing and / or treating respiratory diseases is administered nasally.

[0055] In one embodiment, nasal administration is performed 0.5 hours before coronavirus infection or 0.5 hours after coronavirus infection.

[0056] In one embodiment, GL25E is administered at a dose of no less than 0.4 mg / kg.

[0057] In one embodiment, the CC50 of GRFT and GL25E is greater than 10,000 nM.

[0058] In one embodiment, GRFT and GL25EG prevent and / or treat respiratory diseases by inhibiting influenza A virus surface protein hemagglutinin (HA)-mediated endocytosis.

[0059] Advantages of the present invention include:

[0060] 1. The present invention provides a recombinant expression protein GRFT (griffithsin) and a recombinant fusion expression protein GL25E (griffithsin-L25-EK1) that can effectively inhibit influenza A virus infection. They have good inhibitory activity against influenza A virus and can be used to prepare drugs for preventing and / or treating respiratory diseases caused by influenza A virus or influenza A virus combined with novel coronavirus infection.

[0061] 2. The anti-influenza virus polypeptides of the present invention can increase the anti-coronavirus activity of the anti-coronavirus polypeptides herein.

[0062] 3. The anti-coronavirus polypeptides of the present invention can increase the anti-influenza virus activity of the anti-influenza virus polypeptides herein.

[0063] 4. The present invention provides a polypeptide drug, particularly a prophylactic drug, that can be used for combined COVID-19 and influenza infection. The present invention is particularly useful for preventing influenza A virus-infected individuals or influenza A patients from contracting SARS-CoV-2 or suffering from diseases caused by SARS-CoV-2 (such as novel coronavirus pneumonia).

[0064] 5. The polypeptide of the present invention is particularly suitable for preparation as a drug for nasal administration and has good patient compliance. BRIEF DESCRIPTION OF THE DRAWINGS

[0065] FIG1 is an SDS-PAGE (FIG. a) and Western blot (FIG. b) identification diagram of two recombinantly expressed proteins, GRFT and GL25E, provided by the present invention;

[0066] FIG2 is a graph showing the detection results of the GRFT and GL25E proteins provided by the present invention inhibiting H7N9 (FIG. a), H5N1 / Thailand (FIG. b) and H5N1 / QH (FIG. c) pseudovirus infection in MDCK cells;

[0067] FIG3 is a graph showing the detection results of the GRFT and GL25E proteins provided by the present invention inhibiting live influenza A virus infection in MDCK cells (Figures ad);

[0068] FIG4 shows the purification and identification of influenza A virus surface protein HA1 provided by the present invention (FIG. a) and the detection results of the binding of GRFT and GL25E proteins to HA1 (FIG. b);

[0069] FIG5 is a graph showing the detection results of the binding of GRFT (Fig. a) and GL25E (Fig. b) proteins to HA protein in the presence of mannose provided by the present invention;

[0070] FIG6 shows the test results of the two proteins GRFT and GL25E provided by the present invention inhibiting influenza A virus A / Puerto Rico / 8 / 1934 (H1N1) infection in mice when administered before (a, c, e) and after (b, d, f) challenge;

[0071] FIG7 is a diagram showing the in vitro safety test results of the two proteins GRFT and GL25E provided by the present invention;

[0072] FIG8 is a diagram showing the in vivo safety test results of the two proteins GRFT and GL25E provided by the present invention;

[0073] FIG9 is a graph showing the inhibitory activity test results of the two proteins GRFT and GL25E provided by the present invention against the novel coronavirus Omicron mutant pseudovirus;

[0074] Figure 10 is a graph showing the inhibitory activity of the two proteins GRFT and GL25E provided by the present invention against the live novel coronavirus Omicron BA.2.2;

[0075] FIG11 is a graph showing the inhibitory activity of GRFT and GL25E proteins provided by the present invention against influenza A virus combined with a novel coronavirus pseudovirus infecting two target cells and one target cell simultaneously;

[0076] Figure 12 is a diagram showing the effects of the two proteins GRFT and GL25E provided by the present invention on inhibiting the infection of target cells by the novel coronavirus pseudovirus by preventing influenza A virus. DETAILED DESCRIPTION

[0077] In order to further understand the present invention, the preferred embodiments of the present invention are described below, but it should be understood that these descriptions are only for further illustrating the features and advantages of the present invention, rather than for limiting the claims of the invention. Those skilled in the art can refer to the contents of this article and appropriately improve the process parameters for implementation. It is particularly important to point out that all similar replacements and modifications are obvious to those skilled in the art, and they are all considered to be included in the present invention. The methods and applications of the present invention have been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the methods and applications described herein without departing from the content, spirit and scope of the present invention to implement and apply the technology of the present invention. Although it is believed that those of ordinary skill in the art fully understand the following terms, the following definitions are still stated to help illustrate the subject matter disclosed by the present invention.

[0078] As used herein, Griffithsin, which may be used interchangeably with GRFT polypeptide, is a seaweed-derived lectin that is one of the most potent viral entry inhibitors discovered to date. It is currently being developed as a microbicide with broad-spectrum activity against several enveloped viruses. GRFT can inhibit human immunodeficiency virus (HIV) infection at picomolar concentrations, exceeding the activity of most anti-HIV drugs. As used herein, Griffithsin may have the amino acid sequence set forth in SEQ ID NO. 1 or a variant thereof having one or more amino acid mutations.

[0079] As used herein, "influenza A virus" is the most common influenza virus during the flu season. Symptoms of respiratory illness caused by influenza viruses include fever, sore throat, runny nose, dry cough, headache, sore throat, runny nose, muscle or body pain or gastrointestinal symptoms (vomiting and diarrhea), etc. Influenza A viruses can be divided into 18 HA (H1-H18) subtypes and 11 NA (N1-N11) subtypes based on the differences in surface antigen hemagglutinin (HA) and neuraminidase (NA) antigenicity and genetic characteristics, among which H1-H16 and N1-N9 can be arbitrarily combined to form different subtypes of influenza viruses (such as H1N1, H7N9, H3N2), and two new subtypes, H17N10 and H18N11, are influenza A-like viruses isolated from bats. In this article, influenza A viruses can be selected from H1N1, H3N2, H5N1 and H7N9.

[0080] As used herein, "SARS-CoV-2" refers to severe acute respiratory syndrome coronavirus 2, sometimes also referred to as the novel coronavirus or SARS-CoV-2. As used herein, the term can include wild-type coronaviruses and mutants with S protein mutations, such as one or more of D614G, Omicron BA.1, Omicron BA.2, Omicron BA.3, Omicron BA.5, Omicron BF.7, Omicron BQ.1, and Omicron XBB.

[0081] As used herein, "respiratory disease" refers to a disease or condition of the respiratory system, which may include upper respiratory tract infection, pneumonia, etc. In this article, respiratory disease particularly refers to respiratory diseases caused by viral infections, such as influenza and / or viral pneumonia, respiratory diseases caused by influenza A virus and / or SARS-CoV-2, or their complications.

[0082] As used herein, a peptide or polypeptide refers to a plurality of amino acid residues linked by peptide bonds.

[0083] As used herein, mutation refers to additions, deletions, substitutions, and / or insertions to an amino acid sequence. In this context, a mutation is a conservative amino acid substitution. Any amino acid sequence herein, such as any of SEQ ID NOs. 1-3, may be appropriately modified while retaining the desired activity (e.g., anti-influenza virus activity and / or anti-new coronavirus activity).

[0084] As used herein, "linker" refers to one or more amino acid residues that connect multiple functional polypeptide moieties. For example, the linker is (GS)n, (GGS)n, (GGGS)n, or (GGGGS)n, where n is an integer from 1 to 20, 2 to 15, 3 to 10, or 4 to 8. For example, n can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20.

[0085] As used herein, "nucleic acid" refers to a plurality of nucleotides linked by internucleotides. The internucleotide linkages may be, for example, phosphodiester bonds. The nucleic acid herein may comprise a polynucleotide encoding a polypeptide of the present invention. To facilitate subsequent processing of the polypeptide, the nucleic acid of the present invention may further comprise nucleotides encoding a purification tag, such as a His tag, a GST tag, an MBP tag, a SUMO tag, or a NusA tag, and, when necessary, a nucleotide sequence encoding a leader sequence.

[0086] As used herein, the term "vector" is a nucleic acid delivery vehicle into which a polynucleotide can be inserted. When a vector is capable of expressing a protein encoded by the inserted polynucleotide, the vector is referred to as an expression vector. A vector can be introduced into a host cell by transformation, transduction, or transfection, so that the genetic material elements it carries are expressed in the host cell. Vectors are well known to those skilled in the art and include, but are not limited to, plasmids; phagemids; cosmids; artificial chromosomes, such as yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), or P1-derived artificial chromosomes (PACs); bacteriophages such as lambda phage or M13 phage, and animal viruses. A vector can contain a variety of elements that control expression, including, but not limited to, promoter sequences, transcription initiation sequences, enhancer sequences, selection elements, and reporter genes. In addition, a vector may also contain a replication initiation site. A vector can contain a nucleic acid of the present invention to facilitate introduction into cells for expression. A vector can contain expression control elements, such as a promoter, terminator, and / or enhancer, operably linked to the nucleic acid.

[0087] As used herein, the term "host cell" is a cell into which a nucleic acid molecule has been introduced by molecular biology techniques. These techniques include transfection with viral vectors, transformation with plasmid vectors, and introduction of naked DNA by electroporation, lipofection, and particle gun acceleration. The host cell can be a eukaryotic cell or a prokaryotic cell. For example, a eukaryotic cell is a yeast cell, an animal cell, and / or an insect cell. The prokaryotic cell can be an Escherichia coli cell.

[0088] As used herein, the degree of association between two amino acid sequences or between two nucleotide sequences is described by parameter " sequence identity ".For purposes of the present invention, use as in EMBOSS software package (EMBOSS: European Molecular Biology Open Software Suite, people such as Rice, 2000, Trends Genet. [genetics trend] 16:276-277) (preferred 5.0.0 version or more recent version) Niederman-Wunsch algorithm (Needleman and Wunsch, 1970, J.Mol.Biol. [J.Molecular Biology] 48:443-453) determine the sequence identity between two amino acid sequences.The parameter used is gap opening penalty 10, gap extension penalty 0.5 and EBLOSUM62 (EMBOSS version of BLOSUM62) substitution matrix.The output (using non-simplified option to obtain) of Nieder, who is labeled as " longest identity ", is used as identity percentage and is calculated as follows:

[0089] (number of identical residues × 100) / (length of alignment - total number of gaps in the alignment)

[0090] For purposes of the present invention, the sequence identity between two deoxynucleotide sequences is determined using the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, supra) as implemented by the Needleman program of the EMBOSS software package (EMBOSS: European Molecular Biology Open Software Suite, Rice et al., 2000, supra) (preferred 5.0.0 version or later). The parameters used are a gap opening penalty of 10, a gap extension penalty of 0.5, and an EDNAFULL (EMBOSS version of NCBI NUC4.4) substitution matrix. The output of Needleman, labeled "longest identity," (obtained using the non-simplified option), which is labeled "longest identity," is used as percent identity and is calculated as follows:

[0091] (number of identical deoxyribonucleotides x 100) / (length of alignment - total number of gaps in the alignment)

[0092] In the context of the present invention, conservative amino acid substitutions or conservative substitutions can be defined by substitutions within the amino acid classes reflected in one or more of the following tables:

[0093] Table 1: Conservative categories of amino acid residues:

[0094] Table 2: Physical and functional classification of candidate amino acid residues:

[0095] peptides

[0096] The present invention provides the following polypeptide sequences.

[0097] Table 3: Polypeptides of the present invention

[0098] The GRFT polypeptide may comprise SEQ ID NO.1 or a variant thereof, provided that the variant sequence retains the antiviral activity of the GRFT polypeptide, in particular, the anti-influenza virus (e.g., anti-influenza A virus) activity. The EK1 polypeptide may comprise SEQ ID NO.3 or a variant thereof, provided that the variant sequence retains the antiviral activity of the EK1 polypeptide, in particular, the anti-SARS-CoV-2 activity. The anti-SARS-CoV-2 activity of the EK1 polypeptide has been previously mentioned in multiple papers published by the inventors and patent applications. The fusion protein prepared by the present invention may comprise the amino acid sequence of SEQ ID NO.2 or a variant thereof.

[0099] Unexpectedly, when the inventors fused the GRFT polypeptide to the EK1 polypeptide, they discovered that the GRFT polypeptide could enhance the anti-SARS-CoV-2 activity of the EK1 polypeptide. Furthermore, due to the inherent antiviral properties of the GRFT polypeptide, the fusion protein also possessed additional antiviral activities, such as anti-influenza and / or anti-HIV activity. Furthermore, the inventors unexpectedly discovered that the EK1 polypeptide could also enhance the antiviral activity of the GRFT polypeptide against pseudotyped influenza viruses and certain influenza A virus strains.

[0100] method

[0101] The present invention provides a method for inhibiting the proliferation of influenza virus and / or coronavirus, comprising contacting a cell with the fusion protein herein and / or a GRFT protein comprising the amino acid sequence shown in SEQ ID NO. 1. The method described herein can be an in vitro method or an in vivo method.

[0102] The present invention provides a method for preventing coronavirus infection of influenza virus-infected cells, comprising contacting the cells with the fusion protein herein and / or the GRFT protein comprising the amino acid sequence shown in SEQ ID NO. 1. The method described herein can be an in vitro method or an in vivo method.

[0103] The present invention provides a method for treating and / or preventing influenza virus and / or coronavirus infection, and / or diseases caused by influenza virus and / or coronavirus infection, which comprises administering to a subject the fusion protein described herein and / or a GRFT protein comprising the amino acid sequence shown in SEQ ID NO.1, and / or a composition comprising the fusion protein and / or the GRFT protein.

[0104] The present invention provides a method for preventing influenza A virus-infected persons or influenza A patients from being infected with SARS-CoV-2 or suffering from diseases caused by SARS-CoV-2 (such as novel coronavirus pneumonia), which comprises administering the fusion protein herein and / or the GRFT protein comprising the amino acid sequence shown in SEQ ID NO.1, and / or a composition comprising the fusion protein and / or the GRFT protein to the influenza A virus-infected persons or influenza A patients.

[0105] The composition may include additional anti-influenza drugs and / or anti-coronavirus drugs to increase the therapeutic effect. For example, the anti-influenza drug is an anti-influenza A virus drug, for example, selected from oseltamivir, arbidol, mabaloxavir, peramivir and zanamivir. The anti-coronavirus drug can be selected from monoclave, namatevir, ritonavir, azithromycin, ambavir monoclonal antibody, romisvir monoclonal antibody, sotrovimab, imdevimab, casirivimab, tixagevimab, cilgavimab, bamlanivimab, etesevimab, amubarvimab and romlusevimab. The composition herein can be in the form of tablets, capsules, drop pills, aerosols, pills, powders, solutions, suspensions, emulsions, granules, liposomes, transdermal agents, or lyophilized powders. Preferably, the fusion polypeptide of the present invention, GRFT protein or its composition is prepared as a dosage form for nasal administration. The method of the present invention is particularly suitable for preventing viral infection or related diseases. Prevention does not necessarily mean to be carried out before infection. In this article, prevention can be 3-10 hours before coronavirus infection to 3-10 hours after coronavirus infection, 2-6 hours before coronavirus infection to 2-6 hours after coronavirus infection, 1-4 hours before coronavirus infection to 1-4 hours after coronavirus infection, or 0.5-2 hours before coronavirus infection to 0.5-2 hours after coronavirus infection.

[0106] Herein, the influenza virus may be influenza A virus. The coronavirus may be SARS-CoV-2. For example, the influenza A virus is selected from H1N1, H3N2, H5N1, and H7N9. The SARS-CoV-2 may be selected from wild-type SARS-CoV-2 and mutants with mutations in the S protein, for example, selected from D614G, Omicron BA.1, Omicron BA.2, Omicron BA.3, Omicron BA.5, Omicron BF.7, Omicron BQ.1, and Omicron XBB.

[0107] Pseudovirus preparation

[0108] Pseudoviruses can be prepared using methods known in the art herein. For example, as previously described (L. Lu, Q. Liu, Y. Zhu, K.-H. Chan, L. Qin, Y. Li, Q. Wang, J. F-W. Chan, L. Du, F. Yu, C. Ma, S. Ye, K.-Y. Yuen, R. Zhang, S. Jiang, Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat. Commun. 5, 3067 (2014)), 293T cells were transfected with plasmids comprising the HIV backbone plasmid pNL4-3.Luc.R - .E - and different SARS-CoV-2 mutant S protein expression plasmids. The amino acid sequences of the S proteins of different SARS-CoV-2 mutants are known. Table 4 provides various SARS-CoV-2 variant S protein expression plasmids. One or more of the amino acid sequences of the SARS-CoV-2 mutant S proteins listed in Table 4 can be used herein.

[0109] Table 4:

[0110] use

[0111] The present invention provides the use of the fusion protein, nucleic acid, pharmaceutical composition and / or GRFT protein comprising the amino acid sequence shown in SEQ ID NO.1 described herein in the preparation of a medicament. The medicament can be used to prevent and / or treat respiratory diseases, wherein the respiratory diseases are caused by infection with influenza A virus and / or novel coronavirus, preferably caused by infection with influenza A virus or caused by influenza A virus combined with novel coronavirus. Alternatively, the medicament can be used to prevent influenza A virus-infected persons or influenza A patients from being infected with SARS-CoV-2 or suffering from novel coronavirus pneumonia.

[0112] The present invention provides the fusion proteins, nucleic acids, pharmaceutical compositions, and / or GRFT proteins comprising the amino acid sequence shown in SEQ ID NO. 1 described herein for use in preventing and / or treating respiratory diseases, wherein the respiratory diseases are caused by infection with influenza A virus and / or novel coronavirus, preferably caused by infection with influenza A virus or a combination of influenza A virus and novel coronavirus. For example, the disease is influenza or influenza combined with novel coronavirus pneumonia.

[0113] The fusion protein, nucleic acid, pharmaceutical composition and / or GRFT protein comprising the amino acid sequence shown in SEQ ID NO.1 described herein can also be used to prevent influenza A virus-infected persons or influenza A patients from being infected with SARS-CoV-2 or suffering from novel coronavirus pneumonia.

[0114] The influenza A virus herein can be selected from H1N1, H3N2, H5N1, and H7N9; and / or the severe acute respiratory syndrome coronavirus 2 can be selected from wild-type SARS-CoV-2 and mutants with mutated S proteins, for example, selected from D614G, Omicron BA.1, Omicron BA.2, Omicron BA.3, Omicron BA.5, Omicron BF.7, Omicron BQ.1, and Omicron XBB. The drug can be a drug for nasal administration. The drug can particularly be a prophylactic drug. As mentioned above, prevention does not necessarily mean that it is performed before infection. The fusion polypeptide, polypeptide, or drug herein prevents and / or treats respiratory diseases by inhibiting cellular endocytosis mediated by the influenza A virus surface protein hemagglutinin.

[0115] To make the objectives, technical solutions, and advantages of the present invention more clear, the technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative efforts shall fall within the scope of protection of the present invention.

[0116] Example

[0117] Example 1 Expression, purification and identification of GRFT and GL25E proteins

[0118] 1. After codon optimization, the gene sequences of GRFT and GL25E proteins were double-digested with NdeⅠ and XhoⅠ and inserted into the Escherichia coli expression vector pET28a(+) to obtain recombinant plasmids. The recombinant plasmids were then transformed into Escherichia coli BL21(DE3) and plated on LB plates containing 50 μg / mL kanamycin.

[0119] Table 5

[0120] 2. Select a single positive clone and inoculate it into 5 mL of LB medium (containing 50 μg / mL kanamycin). Pre-culture overnight at 37°C and 220 rpm. Then, inoculate the pre-culture into 1 L of LB medium (containing 50 μg / mL kanamycin) at a ratio of 1:200 and culture at 37°C and 220 rpm until the OD600 value of the bacterial solution reaches approximately 0.5. Place the bacterial solution at 4°C for half an hour, add 1 mM IPTG, and continue to culture at 16°C and 180 rpm for 20 hours.

[0121] 3. After the culture is completed, centrifuge the culture solution at 8000rpm for 3 minutes, collect the bacterial solution, and resuspend it with 100mL of PBS. After ultrasonically disrupting the resuspended bacterial solution, centrifuge it at 10000rpm and 4℃ for 30 minutes, and filter the supernatant with a 0.45μm filter membrane. Take 1mL of nickel column material equilibrated with binding buffer (10mM imidazole, 20mM Na2HPO4, 0.5M NaCl, pH7.4) and add it to the culture supernatant. Bind at room temperature for 2 hours. 4. Pass the liquid in step 3 through the purification column and wash it with 50 volumes of washing buffer (20mM imidazole, 20mM Na2HPO4, 0.5M NaCl, pH7.4). Finally, elute it with 5 volumes of elution buffer (500mM imidazole, 20mM Na2HPO4, 0.5M NaCl, pH7.4). The eluted protein was ultrafiltered 5-6 times, and the buffer was replaced with PBS to obtain the purified fusion protein. 5. The purified protein was subjected to SDS-PAGE protein electrophoresis. After the electrophoresis was completed, Coomassie Brilliant Blue staining and Western blotting were performed for identification. The results are shown in Figure 1, wherein Figure 1 a is an SDS-PAGE identification diagram of the two proteins GRFT and GL25E, and b is a Western blotting identification diagram of the two fusion proteins GRFT and GL25E. As shown in Figure 1, both GRFT and GL25E proteins migrated to positions consistent with the expected band size (GRFT: 16kDa; GL25E: 21kDa). The above-mentioned polypeptides can also be synthesized by commercial companies.

[0122] Example 2 Inhibition of pseudovirus infection of influenza A viruses H7N9 and H5N1 In this example, the H7N9 and H5N1 pseudovirus systems were used as tools to detect the activity of GRFT and GL25E in inhibiting pseudovirus infection on MDCK cells. The specific steps are as follows:

[0123] ①Packaging and preparation of pseudovirus A (H7N9) and pseudovirus A (H5N1):

[0124] The plasmids used to package influenza pseudovirus A(H7N9) are: HA plasmid pVKD-HA (GenBank: KC853228) of A(H7N9), NA plasmid pVKD-NA (GenBank: KC853231) of A(H7N9) and HIV backbone plasmid pNL4-3.Luc.RE- containing luciferase reporter gene. Among them, the HA and NA genes encoded by the pVKD-NA plasmid were obtained from influenza virus A / Shanghai / 4664T / 2013(H7N9) by RT-PCR. The plasmids used for packaging influenza pseudovirus A (H5N1) are a plasmid containing H5N1 (A / QH / 59 / 05) HA (GenBank: ABE68921) or a plasmid containing H5N1 (A / Thailand / Kan353 / 2004) HA (GenBank: EF541411.1), a NA plasmid containing H5N1 (A / Thailand / Kan353 / 2004) N1-type, and an HIV backbone plasmid pNL4-3.Luc.RE- (all of the above plasmids can be provided by the New York Blood Center in the United States or can be purchased directly).

[0125] The preparation process of pseudovirus is as follows:

[0126] 1. Culture HEK 293T cells in DMEM containing 10% fetal bovine serum in a 10 cm culture dish in a 37°C, 5% CO2 incubator. Transfection was performed when the cells reached 50% to 70% confluence.

[0127] 2. 10 μg, 10 μg, and 20 μg of the HA plasmid, NA plasmid, and HIV-1 backbone plasmid used for packaging influenza pseudovirus A (H7N9) were mixed together in 1 mL of 0.9% NaCl solution and allowed to stand at room temperature for 5 minutes.

[0128] 3. Add 10 μL of Vigofect transfection reagent (Vigos Biotechnology (Beijing) Co., Ltd., used with culture medium at a ratio of 1:1000) to another 1 mL of 0.9% NaCl solution and let it stand at room temperature for 5 minutes.

[0129] 4. Add the Vigofect dilution solution dropwise to the plasmid mixture. After standing at room temperature for 15 minutes, add it dropwise to the HEK 293T cells cultured in a T75 culture flask.

[0130] 5. 6 hours after transfection, replace the culture medium with fresh DMEM containing 10% fetal bovine serum.

[0131] 6. After 48 hours of cell culture medium replacement, collect the cell culture medium supernatant, centrifuge at 3000 rpm for 20 minutes, filter the supernatant through a 0.22 μm filter membrane, and store in aliquots at -80°C.

[0132] 7. The packaging and collection process of influenza pseudovirus A (H5N1) is the same as that of influenza pseudovirus A (H7N9) mentioned above.

[0133] ② Experimental process of inhibiting pseudovirus infection of influenza A viruses H7N9 and H5N1.

[0134] 1. GRFT, GL25E, and EK1 were diluted in a gradient in a 96-well round-bottom plate using serum-free DMEM medium to a total of 8 concentrations (as shown in FIG2 ). The drug addition volume per well was 100 μL, and 3 replicates were set for each gradient. GRFT and EK1 served as positive controls. EK1 had an amino acid sequence as shown in SEQ ID NO: 3 and was synthesized by Gill Biochemical Company. GRFT had an amino acid sequence as shown in SEQ ID NO: 1. 2. 100 μL of pseudovirus solution (RLU: 20,000-100,000) was added to the 96-well plate in step (1) of this example (the wells with drug and virus added were marked as drug wells). At the same time, a positive control group (with virus but no drug, i.e., virus wells) and a negative control group (with no virus and no drug, i.e., no drug wells) for virus infection were set up. The virus and drug were incubated at 37° C. for 1 hour.

[0135] 3. 200 μL of the mixture from step (2) of this example was added to a 96-well plate containing MDCK cells (the cells were purchased from the Chinese Academy of Sciences Cell Bank, catalog number: GNO23). The cells were cultured at 37°C and 5% CO2 for 12 hours, and the culture medium was replaced with DMEM containing 10% FBS.

[0136] After 48 hours of continued culture, discard the supernatant and wash the cells once with PBS. Add 50 μL of cell lysis buffer (Promega, Catalog No. 0000389797) and lyse at room temperature for 1 hour. Pipette 40 μL of lysis supernatant into a 96-well assay plate. Add 40 μL of substrate (Promega, Catalog No. 0000369690) and immediately measure fluorescence.

[0137] 5. Calculate the inhibition rate of pseudovirus infection using the following formula: Inhibition rate = (viral wells - drug wells) / (viral wells - drug-free wells) × 100%.

[0138] Figure 2 shows the effects of the GRFT and GL25E proteins provided herein on MDCK cells. As shown in Figure 2, GRFT and GL25E were highly effective in inhibiting infection by H7N9 and H5N1 pseudoviruses, with half-inhibitory concentrations (IC50s) of 63.11 nM and 49.43 nM, respectively, for H7N9; 250.9 nM and 234.3 nM for H5N1 / QH; and 556.0 nM and 527.8 nM for H5N1 / Thailand. The control group, EK1, showed no inhibitory activity. GL25E exhibited improved IC50s compared to GRFT for these influenza pseudoviruses.

[0139] Example 3 GRFT and GL25E inhibit infection with live viruses A / Puerto Rico / 8 / 1934 / (H1N1), A / Guizhou / 54 / 89(H3N2), A / California / 7 / 09(H1N1) and A / WSN / 1933(H1N1)

[0140] After the in vitro inhibition test using the pseudoviruses described above, plaque reduction experiments were conducted on MDCK cells using live A / Puerto Rico / 8 / 1934 / (H1N1), A / Guizhou / 54 / 89(H3N2), A / California / 7 / 09(H1N1), and A / WSN / 1933(H1N1) viruses in this example. The specific steps are as follows.

[0141] 1. MDCK cells were plated in 24-well culture plates 12 hours in advance and cultured in DMEM medium (10% fetal bovine serum) at a density of 1.5 x 10 5 / hole.

[0142] 2. Cells were cultured in a 37°C, 5% CO2 incubator. Plaque assays were performed when the cells were more than 80% confluent.

[0143] 3. Dilute GRFT and GL25E in DMEM medium in a 3-fold gradient.

[0144] 4. Dilute the influenza virus in a 10-fold gradient using DMEM culture medium containing 1 μg / mL TPCK-trypsin.

[0145] 5. First, aspirate the supernatant of the MDCK cell culture medium, wash once with PBS, and then add the virus and peptide mixture to the MDCK cells, 200 μL per well, set up two replicate wells for each concentration (experimental group), add only DMEM culture medium to a group of cell wells as a blank control (infection negative control group), and add the same number of viruses to a group of cell wells as an infection positive control group. Infect at 37°C for 2 hours, shaking and mixing every 15 minutes.

[0146] 6. Heat the pre-prepared and sterilized 3% low melting point agar in a microwave oven, cool to 37°C, and mix with DMEM containing 2 μg / mL TPCK-trypsin preheated at 37°C to make the final concentration of agar 1%.

[0147] 7. First, aspirate the supernatant of MDCK cells, then add 1% low-melting-point agar at 37°C to the cells. After leaving them at room temperature for half an hour, place the cells upside down in a 37°C, 5% CO2 incubator and continue culturing.

[0148] 8. After 48 hours of culture, observe the appearance of clear milky white spots with distinct particles in the 24-well plate, then fix and stain with a solution containing 4% paraformaldehyde solution and 0.5% crystal violet, and leave at room temperature for 4 hours.

[0149] 9. Gently rinse the agar with tap water and let it dry at room temperature.

[0150] 10. Count the number of unstained spots in the 24-well plate and calculate the inhibition rate. Virus entry inhibition rate (%) = 100 × [(mean number of spots in the positive infection control group - mean number of spots in each well of the experimental group) / (mean number of spots in the positive infection control group - mean number of spots in the negative infection control group)].

[0151] 11. Use Excel software to count the number of virus spots in each well and use GraphPad Prism 8.0 software to draw a graph.

[0152] The inhibition rate and concentration curves of GRFT and GL25E against influenza virus entry were plotted and their half-maximal inhibitory concentration (IC50) was calculated.

[0153] The results are shown in Figure 3, wherein a is a graph showing the detection results of GRFT and GL25E inhibiting A / Puerto Rico / 8 / 1934 / (H1N1) live virus infection, b is a graph showing the detection results of GRFT and GL25E inhibiting A / California / 7 / 09(H1N1) live virus infection, c is a graph showing the detection results of GRFT and GL25E inhibiting A / Guizhou / 54 / 89(H3N2) live virus infection, and d is a graph showing the detection results of GRFT and GL25E inhibiting A / WSN / 1933(H1N1) live virus infection.

[0154] As shown in Figure 3, GRFT and GL25E were more effective in inhibiting infection with live influenza A viruses, with IC50 values ​​ranging from 263 to 683 nM and 152 to 519 nM, respectively. GL25E exhibited a higher inhibitory activity against influenza viruses than GRFT. We speculate that the EK1-coupled fusion protein GL25E increased the solubility of GRFT (discovered during recombinant protein preparation), which may have promoted the binding of the peptide to the virus. The control group, EK1, had no inhibitory activity against influenza viruses.

[0155] Example 4 Detection of Binding of GRFT and GL25E to Influenza Virus HA1

[0156] ① Construction and amplification of HA1 protein plasmid:

[0157] 1. Plasmid Construction: The gene expressing the H5N1 (A / QH / 59 / 05) HA1 protein (Genbank: ABE68921) was obtained by PCR (using the H5N1 (A / QH / 59 / 05) HA as the template, the primer sequences are shown in Table 6, and the PCR reaction conditions were: 95°C for 5 minutes, 95°C for 30 seconds, 56°C for 30 seconds, and 72°C for 90 seconds, 36 cycles, and a final cycle of 72°C for 5 minutes). The plasmid was then constructed into the pFuse-Fc vector (invovogen) by enzyme digestion (double digestion with EcoRV and NcoI) and enzyme ligation (T4 DNA ligase), and named the plasmid pFuse-HA1(H5N1 / QH)-Fc.

[0158] Table 6 Primers and sequences

[0159] 2. Pipette 2 μL of the recombinant plasmid identified by sequencing and transform it into TOP10 competent cells. Incubate the mixture on ice for 30 minutes, then at 42°C for 90 seconds. Place on ice again for 3-5 minutes, add 1 mL of LB medium, and continue incubating at 220 rpm at 37°C for 45-60 minutes. Centrifuge at 3000 rpm for 2 minutes. Discard the supernatant and spread the pellet onto a bleomycin-resistant LB plate (YEASEN, Cat: 60216ES60, 1:2000 dilution). Incubate at 37°C for 12 hours.

[0160] 3. Pick a positive single clone and immediately inoculate it into 5 mL of LB culture medium (containing bleomycin, as before), then inoculate it into 200 mL of LB culture medium (containing bleomycin, as before) at a dilution of 1:100, and shake at 37°C for 12 hours;

[0161] 4. Collect the bacterial suspension, extract the plasmid according to the instructions of the plasmid extraction kit (endotoxin-free extraction kit, Magen), determine the concentration by Nanodrop, and freeze at -20°C.

[0162] ② HA1-Fc protein expression:

[0163] 1. Remove Expi293 cells from the liquid nitrogen tank and quickly place them in a 37°C water bath. After the frozen cells thaw, centrifuge at 800g for 3 minutes and discard the freezing solution.

[0164] 2. Add 1 mL of SMM293-TII medium, gently pipette to mix the cells, transfer to a 500 mL flat-bottom triangular shake flask, add 200 mL of medium, and place in a 37°C, 5% CO2 incubator with shaking at 120 rpm.

[0165] 3. Count the cells one day before transfection and transfer them to a new cell culture flask so that the number of cells in the new cell culture flask is 1.5x10 6 cells / mL, and the cell viability was greater than 95% (determined by trypan blue staining).

[0166] 4. Dilute 240 μg of pFuse-HA1(H5N1 / QH)-Fc plasmid and 720 μL of EZtrans (Shanghai Liji Biotechnology Co., Ltd., Lot: LFC23039) to 10 mL with 10 mL of SMM293-TII medium, then add the EZtrans dilution to the plasmid dilution, mix well, and let stand at room temperature for 10 minutes. Then, add the prepared transfection system dropwise to the cells (200 mL of Expi293 cells). Be sure to gently shake the cells while adding the solution dropwise. Continue to place the solution in a 37°C, 5% CO2 incubator with shaking at 120 rpm.

[0167] 5. Add 10 mL of SMM293-TII medium on the second and fifth days after transfection. On the seventh day after transfection, centrifuge at 3,000 rpm for 10 minutes, collect the cell supernatant, and filter it with a 0.45 μm filter for subsequent protein purification.

[0168] ③ HA1-Fc protein affinity chromatography purification:

[0169] 1. Pipette 2 mL of Protein A resin (Genescript, Cat. No.: L00210-200) into the bottom of an affinity chromatography column. Pre-add 1 mL of binding / equilibration buffer (PBS, pH 7.4) to allow the resin to precipitate and the buffer to drain from the column. Rinse the column with 10 column volumes of ultrapure water and then equilibrate with 20 column volumes of equilibration buffer.

[0170] 2. Add the equilibrated column material to the filtered cell supernatant containing the target protein and shake at 200 rpm at 4°C overnight for binding.

[0171] 3. After binding is completed, add the mixture of cell supernatant and column material to the affinity chromatography column material and collect the effluent.

[0172] 4. Wash the column with 30 column volumes of equilibration buffer to remove impurities.

[0173] 5. Add 50 μL of neutralization buffer (1 M Tris-HCl, pH 8.5) to the collection tube in advance, wash the column with 10 column volumes of elution buffer (0.1 M glycine, pH 3.0), and collect the eluate, which is the purified protein; the purified protein HA1-Fc was verified by SDS-PAGE.

[0174] 6. Based on the molecular weight of HA1-Fc protein (about 64kDa), a 10kDa ultrafiltration tube was selected to replace the buffer with PBS with a pH of 7.4. The protein concentration was determined using Nanodrop, and the aliquots were stored at -80°C. ④ Binding experiment of GRFT and GL25E with HA1-Fc

[0175] 1. Add 5 μg / mL of GRFT, GL25E and BSA to a 96-well ELISA plate (Corning) at a volume of 50 μL per well and coat the plate at 37°C for 2 hours.

[0176] 2. Wash with PBST 1-2 times, 5 minutes each time, add 150 μL of blocking solution (PBST containing 2% gelatin), and block at 37°C for 2 hours.

[0177] 3. Wash twice with PBST, 5 minutes each time, add 5-fold serial dilutions of HA1-Fc (initial concentration 5 μg / mL), 50 μL per well, and react at 37°C for 1 hour.

[0178] 4. Wash with PBST 3-4 times, 5 minutes each time. Add 50 μL of HRP-labeled goat anti-human IgG antibody, which can specifically bind to the Fc tag (1:10,000, Abacam, ab97225), and react at 37°C for 1 hour.

[0179] 5. Wash with PBST 4 times, 5 minutes each time. Add 50 μL of TMB colorimetric solution, and after color development, stop the reaction with 50 μL of stop solution (2% H2SO4). Measure the absorbance of each well at OD 450 using a microplate reader.

[0180] The results are shown in Figure 4, where Figure 4a is the identification image of HA1-Fc protein by SDS-PAGE, and Figure 4b is the binding image of GRFT, GL25E and HA1 protein. The results show that HA1 protein can bind to GRFT and GL25E in a concentration-dependent manner, but the unrelated protein BSA cannot bind to them.

[0181] Example 5 Mannose can inhibit the binding of GRFT and GL25E to the HA1 subunit

[0182] 1. 50 μl of HA1 protein (prepared as in Example 4) (5 μg / ml) was added to an ELISA plate (Corning) and placed at 37° C. for 2 h.

[0183] 2. Wash twice with PBST, 5 minutes each time. Add PBST containing 2% gelatin and react at 37°C for 2 hours.

[0184] 3. One hour in advance, add mannose to 5 μg / ml GL25E. The final concentrations of mannose are 0, 50, 100, and 200 mM, respectively. Add equal volumes of PBS to GRFT and GL25E as the control group, and react at 37°C for 1 hour.

[0185] 4. Wash the plate twice with PBST for 5 minutes each time. Add 50 μL of the mixture from step 3 to the coated wells and incubate at 37°C for 1 hour.

[0186] 5. Wash with PBST three times for 5 minutes each time. Add 50 μL of HRP-labeled goat anti-human IgG antibody (1:10,000, Abacam, ab97225) and react at 37°C for 1 hour.

[0187] 6. Wash with PBST 4 times, 5 minutes each time. Add 50 μL of TMB, and after color development, stop the reaction with 50 μL of stop solution (2% H2SO4). Measure the absorbance of each well at OD 450 on a microplate reader.

[0188] The results are shown in Figure 5, where a is the detection result of mannose inhibiting the binding of GRFT to HA1 protein, and b is the detection result of mannose inhibiting the binding of GL25E to HA1. As shown in the figure, mannose can inhibit the binding of GRFT and GL25E to the HA1 subunit. As the mannose concentration increases, the binding of GRFT and GL25E to the HA1 subunit gradually decreases, indicating that GRFT and GL25E bind to the HA1 subunit in a glycosyl-dependent manner.

[0189] Example 6 Detection of GRFT and GL25E Inhibiting Live A / Puerto Rico / 8 / 1934 (H1N1) Virus Infection in Mice

[0190] 1. Preventive Protection Experiment: 6-8 week old female C57BL / 6 mice were randomly divided into five groups of six mice each: a mock group (untreated blank control), a PBS group (virus control group), an EK1 group (drug control group), a GRFT group, and a GL25E group (drug treatment group). The mice were administered intranasally with 10 mg / kg / mouse of the virus 0.5 hour before administration. Half an hour after administration, the mice were challenged intranasally with A / Puerto Rico / 8 / 1934 (H1N1) (hereinafter referred to as PR8) live virus at 10 times the LD50. (In a preliminary experiment, 6-8 week old female C57BL / 6J mice were randomly divided into four groups of four. Four 10-fold serial dilutions of the stock PR8 live virus were used to administer to each group. The median lethal dose (LD50) was determined as the virus dose (dilution factor) that achieved half the mortality rate.)

[0191] 2. Therapeutic Experiment: 6-8 week old female C57BL / 6J mice were similarly selected and divided into five groups of six mice each: a mock group (untreated blank control), a PBS group (virus control group), an EK1 group (drug control group), a GRFT group, and a GL25E group (drug treatment group). Half an hour before the challenge, mice were administered 10 times the LD50 (lethal dose) of A / Puerto Rico / 8 / 1934 (H1N1). Half an hour after the challenge, GL25E 10 mg / kg was administered intranasally, at a dose of 10 mg / kg per mouse.

[0192] 3. Continue to monitor the weight and survival rate of mice and stop recording after 15 days.

[0193] The results are shown in Figure 6, where a is the weight change result of PR8-infected mice that were administered GRFT and GL25E before challenge, b is the survival rate test result of PR8-infected mice that were administered GRFT and GL25E after challenge, c is the weight change result of PR8-infected mice that were administered GRFT and GL25E before challenge, d is the survival rate test result of PR8-infected mice that were administered GRFT and GL25E after challenge, and Figures e and f respectively show the effects of pre- and post-challenge administration on the viral load in the lung tissue of C57BL / 6 mice challenged with A / Puerto Rico / 8 / 1934 (H1N1). As shown in Figure 6, intranasal administration of GRFT and GL25E 0.5 hours before A / (H1N1) / PR8 virus infection can effectively prevent weight loss and mortality caused by A / (H1N1) / PR8 infection, with a protection rate of 100%; intranasal administration of GRFT and GL25E 0.5 hours after A / Puerto Rico / 8 / 1934(H1N1) virus infection has a protection rate of 50%, indicating that the preventive effect of GRFT and GL25E in vivo is better than the therapeutic effect, and can be used for the development of drugs to prevent influenza virus (IAV) infection.

[0194] Example 7 In vitro safety testing of GRFT and GL25E

[0195] 1. Use DMEM medium containing 10% FBS to dilute GRFT and GL25E in a 96-well round-bottom plate to a total of 8 concentrations, with a volume of 120 μL per well and 3 replicates per gradient. At the same time, DMEM medium containing an equal volume of PBS (containing 10% FBS) was used as a cell control well.

[0196] 2. 100 μL of the mixture from step (1) of this example was added to culture wells containing MDCK cells, A549 cells, Calu3 cells, Huh-7 cells, Caco2 cells, and Vero cells (all purchased from the Cell Bank of the Chinese Academy of Sciences). The cells were cultured at 37°C and 5% CO2 for 48 hours.

[0197] 3. The culture supernatant was discarded and CCK-8 (purchased from MCE, catalog number HY-K0301) diluted 20 times with serum-free DMEM was added. After further culture for 1-2 hours, the absorbance of OD450 was detected.

[0198] 4. Calculate cell viability using the formula: cell viability = [(drug well - blank well) / (control well - blank well)] × 100%.

[0199] The results are shown in FIG7 . At a concentration of 10,000 nM, the viability values ​​of cells treated with GRFT and GL25E were both above 70%, indicating that their half cytotoxic concentration (CC50) was greater than 10,000 nM.

[0200] Example 8 In vivo safety testing of GRFT and GL25E

[0201] Similarly, 6-8 week old C57BL / 6J female mice were selected and divided into two groups of 6 mice each. A high dose of GL25E (10 mg / kg) was administered intranasally, with a PBS group serving as a control. After GL25E administration, the mice's weight was monitored every two days for 14 days. As shown in Figure 8a, mice in the GL25E-treated group did not experience weight loss, and there was no significant difference in body weight between the GL25E-treated group and the PBS-treated group. To further verify the in vivo safety of GL25E, serum was collected from mice on days 0, 1, 3, 5, 7, and 9 after administration to measure alanine aminotransferase and creatinine levels (refer to the instructions for the alanine aminotransferase and creatinine assay kits, Nanjing Jiancheng Bioengineering Research Institute). As shown in Figure 8b, there was no significant increase in alanine aminotransferase and creatinine in the GL25E-treated group, and there was no significant difference compared to the PBS-treated group. These results indicate that intranasal administration of GL25E does not cause liver and kidney damage in mice.

[0202] Example 9 Detection of the inhibitory effect of GRFT and GL25E against SARS-CoV-2 Omicron mutant pseudovirus

[0203] This application constructs pseudoviruses of SARS-CoV-2omicron mutant strains B.1.1.529, BA.2, BA.2.12.1, BA.2.2, BA.2.9, BA.3, BA.5, BF.7, XBB, and BQ.1.1, and detects the inhibitory effects of GRFT and GL25E on SARS-CoV-2 mutant strains. The specific steps are as follows:

[0204] ① Packaging and preparation of SARS-CoV-2omicron mutant pseudovirus.

[0205] Backbone plasmid (pNL4-3.Luc.RE-) and envelope protein plasmids corresponding to the pseudovirus to be packaged (pcDNA3.1-B.1.1.529-S, BA.2-S, BA.2.12.1-S, BA.2.2-S, BA.2.9.1-S, BA.3-S, BA.4 / 5-S, BF.7-S, XBB-S, BQ.1.1-S, corresponding Genbank numbers or GISAID numbers are shown in Methods, Pseudovirus Preparation, Table 4). Pseudovirus packaging was performed at a ratio of 28 μg backbone plasmid and 7 μg envelope plasmid, i.e., 4:1. The pseudovirus preparation process was described in Example 2.

[0206] ②Detection of the inhibitory effect of GRFT and GL25E against SARS-CoV-2Omicron mutant pseudovirus.

[0207] 1. Serum-free DMEM medium was used to gradient dilute GRFT, GL25E and EK1 in a 96-well round-bottom plate, with a total of 8 dilution concentrations (as shown in Figure 9). The volume of each well was 60 μL, and 3 replicates were set for each gradient.

[0208] 2. 60 μL of pseudovirus solution (RLU: 20,000-100,000) was added to the 96-well plate in step (1) of this example (the wells with drug and virus added were denoted as drug wells). At the same time, a positive control group (with virus but no drug, i.e., virus wells) and a negative control group (with no virus and no drug, i.e., no drug wells) for virus infection were set up. The virus and drug were incubated at 37°C for 1 hour.

[0209] 3. 100 μL of the mixture in step (2) of this example was added to a 96-well plate containing Caco2 cells. The cells were cultured at 37°C and 5% CO2 for 12 hours, and the culture medium was replaced with DMEM containing 10% FBS.

[0210] After 48 hours of continued culture, discard the supernatant and wash the cells once with PBS. Add 50 μL of cell lysis buffer (Promega, Catalog No. 0000389797) and lyse at room temperature for 1 hour. Pipette 40 μL of lysis supernatant into a 96-well assay plate. Add 40 μL of substrate (Promega, Catalog No. 0000369690) and immediately measure fluorescence.

[0211] 5. Calculate the inhibition rate of pseudovirus infection using the following formula: Inhibition rate = (viral wells - drug wells) / (viral wells - drug-free wells) × 100%.

[0212] The results are shown in Figure 9, which show that GL25E is significantly better than EK1 and GRFT in inhibiting mutant infection. This suggests that GRFT can improve the anti-SARS-CoV-2 activity of EK1.

[0213] Example 9 Detection of the inhibitory effect of GRFT and GL25E against the live virus of the Omicron mutant BA.2.2

[0214] In this example, real-time fluorescence quantitative PCR was used to determine the inhibitory effect of GRFT and GL25E on the live SARS-CoV-2Omicron BA.2.2 virus (virus infection and lysis experiments were performed in a BSL-3 laboratory). The specific steps are as follows.

[0215] ① Virus infection experiment

[0216] 1. Use serum-free DMEM medium to gradient dilute GRFT, GL25E and EK1 in a 96-well round-bottom plate, with a total of 6 dilution concentrations. The volume of each well is 60 μL, and each gradient is set up for 3 replicates.

[0217] 2. Add 60 μL of the diluted BA.2.2 live virus solution (MOI = 0.01) to the 96-well plate in step (1) of this example (the wells with drug and virus are denoted as drug wells). At the same time, set up a positive control group for virus infection (with virus but no drug, i.e., virus wells) and a negative control group (with no virus and no drug, i.e., no drug wells). Incubate the virus and drug at 37°C for 1 hour.

[0218] 3. 100 μL of the mixture from step (2) of this example was added to a 96-well plate containing Caco2 cells. The cells were cultured at 37°C, 5% CO2 for 1 hour, and the culture medium was replaced with DMEM containing 2% FBS. The cells were then cultured in a 37°C incubator for 48 hours.

[0219] 4. After 48 hours, 50 μl of cell supernatant was transferred to a 1.5 ml screw-cap tube and 3 volumes of Buffer RZ (TIANGEN, Lot#X1221) were added to lyse the virus.

[0220] ②RNA extraction

[0221] RNA was extracted according to the instructions of the RNA simple Total RNA Kit (Lot#X1117). The specific steps are as follows:

[0222] 1. Use 3 times the volume of the sample to lyse the virus-containing supernatant with RZ, and repeatedly pipette and aspirate several times to ensure uniform lysis.

[0223] 2. Place at room temperature for 5 minutes to allow the nucleoprotein complex to completely dissociate.

[0224] 3. Add 0.12 mL of chloroform to 0.45 mL of RZ lysate and shake to mix.

[0225] 4. Incubate at room temperature for 2-3 minutes to allow the organic and aqueous phases to separate, then centrifuge at 12,000 g for 15 minutes at 4°C.

[0226] 5. After centrifugation, RNA exists in the upper aqueous phase. Carefully pipette the upper aqueous phase into a new EP tube, taking care not to aspirate the middle DNA layer and the lower organic phase.

[0227] 6. Slowly add 0.5 times the volume of anhydrous ethanol and mix thoroughly. Transfer the resulting solution and precipitate to adsorption column CR3 and centrifuge at 12,000 rpm for 30 seconds at 4°C. Discard the waste liquid in the collection tube.

[0228] 7. Add 500 μL of deproteinized solution RD (with ethanol) to the adsorption column CR3, centrifuge at 12,000 rpm at 4°C for 30 seconds, discard the waste liquid, and place CR3 in a collection tube.

[0229] 8. Add 500 μL of rinse solution RW (with ethanol added) to the adsorption column CR3, let it stand at room temperature for 2 minutes, centrifuge at 12,000 rpm at 4°C for 30 seconds, and discard the waste liquid.

[0230] 9. Repeat step 8.

[0231] 10. Place the adsorption column in a 2 mL collection tube and centrifuge at 12,000 rpm at 4°C for 2 minutes to remove residual liquid.

[0232] 11. Transfer the adsorption column CR3 to a new 1.5 mL centrifuge tube, add 100 μL of RNase-Free ddH2O, let it stand at room temperature for 2 minutes, and centrifuge it at 12,000 rpm for 2 minutes at 4°C.

[0233] ③ q-PCR detection of viral copy number

[0234] The detection was performed using a Bio-Rad CFX96 fluorescence quantitative PCR instrument. The primers and probes were synthesized by BGI, and the sequences are as follows:

[0235] Table 7 Primer and probe sequences

[0236] The reaction system was configured as follows, with three replicate wells for each sample, and the HiScript II One Step qRT-PCR Probe Kit (Vazyme) was used for detection:

[0237] Table 8 HiScript II One Step qRT-PCR Probe Kit (Vazyme) reaction system

[0238] The reaction conditions were: 42°C for 5 minutes, 95°C for 10 seconds; 95°C for 5 seconds, 50°C for 30 seconds, 72°C for 30 seconds, 40 cycles.

[0239] The results of fluorescence quantitative PCR are shown in Figure 10. Compared with the EK1 peptide, GL25E and GRFT proteins can effectively inhibit the infection of Caco2 cells by live SARS-CoV-2 virus, with IC50 values ​​of 6.88 nM and 82.20 nM, respectively, which are 64 times and 5 times that of the EK peptide (IC50 = 438.90 nM). This indicates that GRFT can improve the anti-SARS-CoV-2 activity of EK1.

[0240] Example 10 Inhibitory Effects of GRFT and GL25E on Influenza Virus Combined with SARS-CoV-2 Infection

[0241] This example establishes two in vitro models of SASR-CoV-2 and IAV co-infection.

[0242] ① Model 1 uses two pseudovirus systems, SASR-CoV-2-SD614G and H5N1 / Thailand (SASR-CoV-2-SD614G pseudovirus uses pNL4-3.Luc.RE- as the backbone plasmid, and the corresponding envelope protein plasmid PcDNA3.1SARS-CoV-2-SD614G (GISAID: EPI_ISL_412912), and the pseudovirus is packaged at a mass ratio of 4:1. The H5N1 / Thailand pseudovirus packaging refers to Example 2, and the pseudovirus preparation process refers to Example 2) to simulate the simultaneous infection of the new coronavirus and influenza A virus in vivo, and detect the effects of GRFT and GL25E on Caco-2 cells and A549 cells or on Calu3 cells alone to inhibit the simultaneous infection of host cells by the two pseudoviruses. The specific steps are as follows.

[0243] 1. Use serum-free DMEM medium to gradient dilute GRFT, GL25E and EK1 in a 96-well round-bottom plate, with a total of 8 dilution concentrations. The volume of each well is 60 μL, and each gradient is set up with 3 replicates. EK1 is used as a negative control.

[0244] 2. 60 μL of a mixture of two pseudoviruses containing SARS-CoV-2 and IAV (RLU: 20,000-100,000) was added to the 96-well plate in step (1) of this embodiment (the wells with drugs and viruses were recorded as drug wells), the drug control well (EK1), and a positive control group for virus infection (with virus but no drug, i.e., virus wells) and a blank control group (with no virus and no drug, i.e., no drug wells) were set up at the same time. The virus and drug were incubated at 37°C for 1 hour.

[0245] 3. 100 μL of the mixture in step (2) of this example was added to a 96-well plate containing Caco2 and A549 cells. The cells were cultured at 37°C and 5% CO2 for 12 hours, and the culture medium was replaced with DMEM containing 10% FBS.

[0246] After 48 hours of continued culture, discard the supernatant and wash the cells once with PBS. Add 50 μL of cell lysis buffer (Promega, Catalog No. 0000389797) and lyse at room temperature for 1 hour. Pipette 40 μL of lysis supernatant into a 96-well assay plate. Add 40 μL of substrate (Promega, Catalog No. 0000369690) and immediately measure fluorescence.

[0247] 5. Calculate the inhibition rate of pseudovirus infection using the following formula: Inhibition rate = (viral wells - drug wells) / (viral wells - drug-free wells) × 100%.

[0248] The results are shown in Figure 11. Figure 11a shows the inhibitory effects of GRFT, GL25E and EK1 on Caco2 and A549 cells, and b shows the inhibitory effects of GRFT, GL25E and EK1 on Calu3 cells alone. As shown in Figure 11a, GL25E can effectively inhibit the simultaneous infection of Caco2 and A549 cells by SARS-CoV-2 and IAV pseudoviruses, and its inhibitory effect is stronger than that of GRFT and EK1 alone. In Figure 11b, GL25E can also effectively inhibit the simultaneous infection of Calu3 cells by SARS-CoV-2 and IAV pseudoviruses, and its inhibitory effect is also better than that of GRFT and EK1 alone.

[0249] ② Model 2 uses the live IAV virus and SARS-CoV-2-S (WT) pseudovirus system (VSV-ΔG rLuc as the backbone, SARS-CoV-2-S-Δ18 (the S envelope protein with 18 amino acids deleted from the end of the SARS-CoV-2-S protein) to package the pseudovirus) as tools to simulate the model in which IAV infection promotes SARS-CoV-2 infection. GRFT and GL25E are tested on MDCK, A549, and Calu3 cells, respectively, to reduce the effect of coinfection with the new coronavirus by inhibiting influenza virus. The specific steps are as follows:

[0250] i. Preparation of SARS-CoV-2-S (WT) (VSV-ΔG rLuc backbone) pseudovirus.

[0251] 1. 24 hours before transfection, plate 293T cells in a 10 cm tissue culture dish and culture at 37°C with 5% CO2. The cells were allowed to reach 60% confluence the next day.

[0252] 2. Use Vigofect transfection reagent to transfect 30 μg of SARS-CoV-2-S (WT)-Δ18 envelope plasmid into 293T cells.

[0253] 3. After culturing at 37°C for 6 hours under 5% CO2, VSV-ΔG rLuc backbone (VSV-G pseudovirions with VSV-ΔG rLuc as backbone, stored in this laboratory) was added.

[0254] 4. After 2 hours of infection, discard the 293T cell supernatant and add DMEM medium containing 10% FBS.

[0255] 5. After 72 hours of continued culture, the supernatant containing VSV-ΔG rLuc pseudoviral particles supplemented with VSV-G was collected and centrifuged at 3000 rpm for 10 minutes to remove cell debris. The supernatant was filtered through a 0.45 μM sterile filter, aliquoted, and stored at -80°C until use.

[0256] ii. In this example, live A / WSN / 1933 (H1N1) virus was used to infect MDCK, A549, and Calu3 cells, respectively. The specific steps are as follows.

[0257] 1. MDCK cells (24 hours in advance), A549 cells (24 hours in advance) and Calu3 cells (48 hours in advance) were plated in 96-well culture plates and cultured in DMEM medium (10% fetal bovine serum) at a density of 1 x 10 4 / hole, 2x 10 4 / hole and 3x 10 4 / well; cultured in DMEM medium containing 15% FBS, the cells were cultured at 37°C, 5% CO2 incubator, and the experiment was performed when the cells were confluent to more than 80%.

[0258] 2. Mix virus A / WSN / 1933 (H1N1) with GRFT, GL25E, or EK1 (negative control). Set up positive control wells (wells with IAV virus but no drug) and blank control wells (mock wells without IAV virus and no drug) and incubate at 37°C for 1 hour.

[0259] 3. Add the virus and inhibitor mixture to MDCK cells, A549 cells and Calu3 cells respectively. After 6-8 hours of virus infection, replace the cell medium with fresh DMEM medium containing 2% FBS.

[0260] 4. After 12 hours of IAV infection, the cell culture supernatant was discarded, and SARS-CoV-2 pseudovirus (VSV-ΔG rLuc backbone) (RLU: 200,000) was added and cultured for another 24 hours.

[0261] 5. Gently wash the remaining culture medium on the cell surface with 1× PBS at room temperature. Add 30 μL of room-temperature equilibrated cell lysis buffer (Renilla Luciferase Assay Lysis Buffer, Promega, E291A-C) to each well. Shake on a shaker at room temperature for 30 minutes until the cells are completely lysed. Transfer 15 μL of the cell lysate to a 96-well plate.

[0262] 6. Add 40 μL of Renilla Luciferase (Promega, E2820) colorimetric substrate to each well and detect relative luciferase activity (RLU).

[0263] The test results are shown in Figure 12. The A / A / WSN / 1933 (H1N1) pre-infection group significantly promoted the infection of SARS-CoV-2 pseudovirus compared with the Mock (no IAV pre-infection group) group in MDCK, A549 and Calu3 cells, thereby establishing an in vitro IAV co-infection SARS-CoV-2 model; in this model, in this example, GL25E and GRFT first acted on IAV, and then were infected with SARS-CoV-2 pseudovirus. The results are shown in Figure 12. Compared with EK1, GRFT and GL25E further reduced the co-infection of SARS-CoV-2 by inhibiting IAV infection.

Claims

1. A fusion protein comprising a first polypeptide and a second polypeptide, wherein the first polypeptide comprises the amino acid sequence shown in SEQ ID NO.1 or a variant amino acid sequence thereof having one or more amino acid mutations, and the second polypeptide comprises the amino acid sequence shown in SEQ ID NO.3 or a variant amino acid sequence thereof having one or more amino acid mutations, and the first polypeptide and the second polypeptide are directly connected or connected through a linker; Preferably, the first polypeptide is at the N-terminus or C-terminus of the second polypeptide; Preferably, the joint is a flexible joint; Preferably, the linker is (GS)n, (GGS)n, (GGGS)n, or (GGGGS)n, where n is an integer of 1-20, 2-15, 3-10, or 4-8; Preferably, the linker is (GGGGS)5; Preferably, the fusion protein comprises the amino acid sequence shown in SEQ ID NO.2; Preferably, the mutation is a substitution, insertion, deletion and / or addition, preferably a conservative amino acid substitution; Preferably, the fusion protein consists of the amino acid sequence of SEQ ID NO.

2.

2. Nucleic acid encoding the fusion protein according to claim 1, preferably comprising the sequence shown in SEQ ID NO.

5.

3. A vector comprising the nucleic acid according to claim 2, Optionally, wherein the vector comprises nucleotides encoding a purification tag, nucleotides encoding a leader and / or a regulatory element; Preferably, the purification tag is selected from a His tag, a GST tag, an MBP tag, a SUMO tag or a NusA tag; Preferably, the regulatory element is selected from a promoter, a terminator and / or an enhancer.

4. A host cell comprising the nucleic acid according to claim 2 or the vector according to claim 3; Preferably, the host cell is a eukaryotic cell or a prokaryotic cell; Preferably, the eukaryotic cell is a yeast cell, an animal cell and / or an insect cell, and / or the prokaryotic cell is an E. coli cell.

5. A pharmaceutical composition comprising the fusion protein according to claim 1, the nucleic acid according to claim 2 and / or the vector according to claim 3, and further comprising a pharmaceutically acceptable carrier; Preferably, the composition comprises an additional anti-influenza drug and / or an anti-coronavirus drug; Preferably, the anti-influenza drug is an anti-influenza A virus drug, for example, selected from oseltamivir, abiraterone dole, mabaloxavir, peramivir, and zanamivir; Preferably, the anti-coronavirus drug is selected from mononavir, namatevir, ritonavir, azithromab, ambavir, romisvir, sotrovimab, imdevimab, casirivimab, tixagevimab, cilgavimab, bamlanivimab, etesevimab, amubarvimab and romlusevimab; Preferably, the composition is in the form of tablets, capsules, pellets, aerosols, pills, powders, solutions, suspensions, emulsions, granules, liposomes, transdermal preparations, or lyophilized powders.

6. An in vitro method for inhibiting the proliferation of influenza virus and / or coronavirus or preventing coronavirus infection of influenza virus-infected cells, comprising contacting the cells with the fusion protein of claim 1 and / or the GRFT protein comprising the amino acid sequence shown in SEQ ID NO.1; wherein the influenza virus is influenza A virus, and the coronavirus is SARS-CoV-2; Preferably, the influenza A virus is selected from H1N1, H3N2, H5N1 and H7N9; Preferably, SARS-CoV-2 is selected from wild-type SARS-CoV-2 and mutants in which the S protein is mutated, for example, selected from D614G, Omicron BA.1, Omicron BA.2, Omicron BA.3, Omicron BA.5, Omicron BF.7, Omicron BQ.1 and Omicron XBB.

7. Use of the fusion protein of claim 1, the nucleic acid of claim 2, the pharmaceutical composition of claim 5 and / or the GRFT protein comprising the amino acid sequence shown in SEQ ID NO.1 in the preparation of a medicament for preventing and / or treating respiratory diseases, wherein the respiratory diseases are caused by infection with influenza A virus and / or SARS-CoV-2, preferably caused by infection with influenza A virus or caused by influenza A virus combined with SARS-CoV-2, such as influenza or influenza combined with novel coronavirus pneumonia, or the medicament is used to prevent influenza A virus-infected persons or influenza A patients from being infected with SARS-CoV-2 or suffering from diseases caused by SARS-CoV-2, such as novel coronavirus pneumonia.

8. The use according to claim 7, wherein the influenza A virus is selected from H1N1, H3N2, H5N1 and H7N9; and / or the severe acute respiratory syndrome coronavirus 2 is selected from wild-type SARS-CoV-2 and mutants in which the S protein is mutated, for example, selected from D614G, Omicron BA.1, Omicron BA.2, Omicron BA.3, Omicron BA.5, Omicron BF.7, Omicron BQ.1 and Omicron XBB; Preferably, the drug is a drug for nasal administration; Preferably, the drug is a preventive drug; Preferably, the drug is taken 3 hours before coronavirus infection to 3 hours after coronavirus infection, 2 hours before coronavirus infection to 2 hours after coronavirus infection, 1 hour before coronavirus infection to 1 hour after coronavirus infection, or drugs administered from 0.5 hours before coronavirus infection to 0.5 hours after coronavirus infection; Preferably, the drug prevents and / or treats respiratory diseases by inhibiting the cellular endocytosis mediated by hemagglutinin, a surface protein of influenza A virus.

9. A method, which is a method for increasing the anti-coronavirus activity of an anti-coronavirus polypeptide, a method for increasing the anti-influenza virus activity of an anti-influenza virus, and / or a method for adding anti-influenza virus activity when the anti-coronavirus activity of an anti-coronavirus polypeptide is increased, comprising fusing an anti-influenza virus polypeptide with an anti-coronavirus polypeptide, wherein the anti-coronavirus polypeptide comprises the amino acid sequence shown in SEQ ID NO.3 or a variant amino acid sequence thereof having one or more amino acid mutations, and the anti-influenza virus polypeptide comprises the amino acid sequence shown in SEQ ID NO.1 or a variant amino acid sequence thereof having one or more amino acid mutations, and the fusion is performed by directly connecting the anti-influenza virus polypeptide and the anti-coronavirus polypeptide or connecting them through a linker; wherein the coronavirus is SARS-CoV-2; and the influenza virus is influenza A virus; Preferably, the influenza A virus is selected from H1N1, H3N2, H5N1 and H7N9; Preferably, SARS-CoV-2 is selected from wild-type SARS-CoV-2 and mutants in which the S protein is mutated, for example, selected from D614G, Omicron BA.1, Omicron BA.2, Omicron BA.3, Omicron BA.5, Omicron BF.7, Omicron BQ.1 and Omicron XBB.

10. The method according to claim 9, wherein the anti-coronavirus polypeptide is at the N-terminus or C-terminus of the anti-influenza virus polypeptide; Preferably, the joint is a flexible joint; Preferably, the linker is (GS)n, (GGS)n, (GGGS)n, or (GGGGS)n, where n is an integer of 1-20, 2-15, 3-10, or 4-8; Preferably, the linker is (GGGGS)5; Preferably, the fusion protein comprises the amino acid sequence shown in SEQ ID NO.2; Preferably, the mutation is a substitution, insertion, deletion and / or addition, preferably a conservative amino acid substitution.

Citation Information

Patent Citations

  • Composition for treating and / or preventing influenza, method and application thereof

    CN109675042A

  • Use of fusion protein in preparing medicine for preventing and / or treating respiratory diseases

    CN113559239A

  • Application of recombinant expression protein in preventing / or treating respiratory diseases

    CN117304335A

  • Griffithsin for use in a method of preventing or treating infections with respiratory viruses

    WO2022268864A1

Cited By

  • Application of recombinant expression protein in preventing / or treating respiratory diseases

    CN117304335A

  • Application of GRFT and fusion protein thereof in paramyxovirus or new coronavirus infection

    CN121513164A

  • Use of grft and its fusion proteins in paramyxovirus or novel coronavirus infection

    CN121513164B

  • Application of VTI1A gene

    CN121648152A